JP7223989B2 - 免疫調節組成物およびその使用方法 - Google Patents

免疫調節組成物およびその使用方法 Download PDF

Info

Publication number
JP7223989B2
JP7223989B2 JP2018506211A JP2018506211A JP7223989B2 JP 7223989 B2 JP7223989 B2 JP 7223989B2 JP 2018506211 A JP2018506211 A JP 2018506211A JP 2018506211 A JP2018506211 A JP 2018506211A JP 7223989 B2 JP7223989 B2 JP 7223989B2
Authority
JP
Japan
Prior art keywords
fold
individual
immunomodulatory composition
cells
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018506211A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531886A5 (enExample
JP2018531886A (ja
Inventor
アグラワル，バビタ
クマー，ラケシュ
グプタ，ナンシー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2018531886A publication Critical patent/JP2018531886A/ja
Publication of JP2018531886A5 publication Critical patent/JP2018531886A5/ja
Application granted granted Critical
Publication of JP7223989B2 publication Critical patent/JP7223989B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2018506211A 2015-08-25 2016-08-22 免疫調節組成物およびその使用方法 Active JP7223989B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562209693P 2015-08-25 2015-08-25
PCT/IB2016/055016 WO2017033123A1 (en) 2015-08-25 2016-08-22 Immunomodulatory compositions and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018531886A JP2018531886A (ja) 2018-11-01
JP2018531886A5 JP2018531886A5 (enExample) 2019-09-26
JP7223989B2 true JP7223989B2 (ja) 2023-02-17

Family

ID=58100011

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018506211A Active JP7223989B2 (ja) 2015-08-25 2016-08-22 免疫調節組成物およびその使用方法

Country Status (7)

Country Link
US (3) US11065283B2 (enExample)
EP (2) EP3341017B1 (enExample)
JP (1) JP7223989B2 (enExample)
CN (1) CN107921113B (enExample)
AU (2) AU2016311387B2 (enExample)
HK (1) HK1248531A1 (enExample)
WO (1) WO2017033123A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017214383A1 (en) * 2016-06-10 2017-12-14 The Johns Hopkins University USE OF C1q/TNF-RELATED PROTEIN-1 (CTRP1) TO TREAT FATTY LIVER DISEASE
CN108888762A (zh) * 2018-08-15 2018-11-27 福建傲农生物科技集团股份有限公司 一种含益生菌代谢产物的组合物
US20250009815A1 (en) * 2019-02-12 2025-01-09 Sanzyme Biologics Private Limited Composition for competitive inhibition of pathogens and restoration of microbial ecological balance
CN109966320B (zh) * 2019-04-26 2022-08-05 青岛东海药业有限公司 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
CN114555103B (zh) * 2019-06-03 2026-06-05 伊美诺路克斯国际公司 用于治疗疾病的天花疫苗和干细胞
KR102149102B1 (ko) * 2019-07-05 2020-08-27 에스케이바이오랜드 주식회사 피부보습 및 피부재생 기능이 있는 더모바이오틱스 블록 조성물의 제조방법
EP3838269A1 (en) * 2019-12-16 2021-06-23 European Molecular Biology Laboratory Compounds and pharmaceutical compositions for prevention and/or treatment of dysbiosis and antibacterial antidotes for microbiome-protection
CN113440609A (zh) * 2020-03-27 2021-09-28 北京市农林科学院 一种双链rna复合物autp及其在疫苗制备中的应用
US10973908B1 (en) 2020-05-14 2021-04-13 David Gordon Bermudes Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine
US12537071B1 (en) 2020-07-22 2026-01-27 David Gordon Bermudes Bacteria having boolean control pathways expressing therapeutic proteins including immunotherapeutic cytotoxins
CN113198004B (zh) * 2021-05-19 2022-08-19 天津市宝恒生物科技有限公司 一种修复肠粘膜的凝结芽孢杆菌制剂
CN113975278B (zh) * 2021-10-29 2023-04-07 中国科学院昆明动物研究所 溴隐亭在制备治疗非洲猪瘟的产品中的应用
WO2023183875A2 (en) * 2022-03-24 2023-09-28 The Brigham And Women's Hospital, Inc. Treatment of perivascular fibrosis and other hypertensive diseases and conditions
AU2024234831A1 (en) * 2023-03-15 2025-10-02 Topelia Aust Limited (Acn 652 771 670) Products of manufacture and therapeutic compositions for treating, ameliorating or preventing viral infections and methods for making and using them
CN117357777B (zh) * 2023-10-30 2026-08-04 重庆国际免疫创新中心有限公司 一种用于治疗多发性硬化症的微针贴及其应用
US12268717B1 (en) 2024-03-01 2025-04-08 Malireddy S. Reddy Enhanced microbial therapeutic agents
WO2025226956A1 (en) * 2024-04-26 2025-10-30 The Board Of Trustees Of The University Of Illinois Catechol o-methyltransferase inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104656A1 (en) 2014-01-07 2015-07-16 Babita Agrawal Immunomodulatory compositions and methods of use thereof

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
WO1990014837A1 (en) 1989-05-25 1990-12-13 Chiron Corporation Adjuvant formulation comprising a submicron oil droplet emulsion
US5736371A (en) 1991-06-04 1998-04-07 A Et S Biovecteurs Biodegradable particulate vector for transporting molecules having biological activity
ES2141108T3 (es) 1991-07-02 2000-03-16 Inhale Inc Metodo y dispositivo para proporcionar medicamentos en aerosol.
US5711968A (en) 1994-07-25 1998-01-27 Alkermes Controlled Therapeutics, Inc. Composition and method for the controlled release of metal cation-stabilized interferon
DE69313134T2 (de) 1992-06-25 1998-02-26 Smithkline Beecham Biolog Adjuvantien enthaltende impfstoffzusammensetzung
US5785049A (en) 1994-09-21 1998-07-28 Inhale Therapeutic Systems Method and apparatus for dispersion of dry powder medicaments
KR100310510B1 (ko) 1993-03-23 2002-07-04 장 스테판느 3-0-탈아세틸화모노포스포릴지질a를함유하는백신조성물
US5497763A (en) 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
JP3220331B2 (ja) 1993-07-20 2001-10-22 エチコン・インコーポレーテツド 非経口投与用の吸収性液体コポリマー類
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AU713040B2 (en) 1994-07-15 1999-11-18 University Of Iowa Research Foundation, The Immunomodulatory oligonucleotides
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
WO1998016247A1 (en) 1996-10-11 1998-04-23 The Regents Of The University Of California Immunostimulatory polynucleotide/immunomodulatory molecule conjugates
EP0842657A1 (en) 1996-11-19 1998-05-20 OctoPlus B.V. Microspheres for controlled release and processes to prepare these microspheres
CA2281838A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated cpg dinucleotide in the treatment of lps-associated disorders
AU753688B2 (en) 1997-03-10 2002-10-24 Ottawa Civic Loeb Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
EP1003531B1 (en) 1997-05-20 2007-08-22 Ottawa Health Research Institute Processes for preparing nucleic acid constructs
WO1998055609A1 (en) 1997-06-06 1998-12-10 The Regents Of The University Of California Inhibitors of dna immunostimulatory sequence activity
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
US6153211A (en) 1997-07-18 2000-11-28 Infimed, Inc. Biodegradable macromers for the controlled release of biologically active substances
EP1279401B1 (en) 1997-09-05 2008-01-09 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
AU2484399A (en) 1998-01-30 1999-08-16 Scios Inc. Controlled release delivery of peptide or protein
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
BR9909915A (pt) 1998-04-09 2000-12-26 Smithkline Beecham Biolog Composições adjuvantes
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
ES2284287T3 (es) 1998-10-16 2007-11-01 Glaxosmithkline Biologicals S.A. Sistemas adyuvantes y vacunas.
US6143314A (en) 1998-10-28 2000-11-07 Atrix Laboratories, Inc. Controlled release liquid delivery compositions with low initial drug burst
CA2363146A1 (en) * 1999-02-22 2000-08-31 Solomon Langermann Caulobacter lps immunoadjuvant
CA2366152A1 (en) 1999-03-19 2000-09-28 Smithkline Beecham Biologicals S.A. Streptococcus pneumoniae vaccine
DK1187629T3 (da) 1999-04-19 2005-01-17 Glaxosmithkline Biolog Sa Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
IL148671A0 (en) 1999-09-24 2002-09-12 Smithkline Beecham Biolog Adjuvant comprising a polyxyethylene alkyl ether or ester and at least one nonionic surfactant
HK1049106A1 (zh) 1999-09-24 2003-05-02 Smithkline Beecham Biologicals S.A. 聚氧化乙烯山梨糖酯和octooxynol的聯用做為佐劑和其在疫苗中的用途
US6458398B1 (en) 1999-10-18 2002-10-01 Eco Pure Food Safety Systems, Inc. Cold water disinfection of foods
EP1255823A4 (en) 2000-01-28 2007-10-31 Azopax Therapeutics Llc PROTEIN POLYMERS WITH SLOW RELEASE
US6296842B1 (en) 2000-08-10 2001-10-02 Alkermes Controlled Therapeutics, Inc. Process for the preparation of polymer-based sustained release compositions
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015104656A1 (en) 2014-01-07 2015-07-16 Babita Agrawal Immunomodulatory compositions and methods of use thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Abraham, W. R. et al.，Phylogeny and polyphasic taxonomy of Caulobacter species. Proposal of Maricaulis gen. nov. with Mari，Int J Syst Bacteriol，Vol.49, Pt.3，1999年，p.1053-1073，(abstract)，PubMed [online]; U.S. National Library of Medicine, [2022年6月28日検索], インターネット＜URL: https://pubmed.ncbi.nlm.nih.gov/10425763/＞
Bhatnagar, P. K. et al.，Anti-tumor effects of the bacterium Caulobacter crescentus in murine tumor models，Cancer Biology & Therapy，2006年，Vol.5, No.5，p.485-491，doi: 10.4161/cbt.5.5.2553

Also Published As

Publication number Publication date
EP3341017A1 (en) 2018-07-04
EP4480544A3 (en) 2025-03-26
US11419904B2 (en) 2022-08-23
AU2016311387B2 (en) 2023-02-23
EP4480544A2 (en) 2024-12-25
JP2018531886A (ja) 2018-11-01
AU2023203076A1 (en) 2023-06-08
CN107921113B (zh) 2026-08-11
US20210369792A1 (en) 2021-12-02
EP3341017A4 (en) 2019-07-17
WO2017033123A1 (en) 2017-03-02
US11065283B2 (en) 2021-07-20
US11701393B2 (en) 2023-07-18
US20230084577A1 (en) 2023-03-16
US20180243347A1 (en) 2018-08-30
AU2023203076B2 (en) 2026-06-11
HK1248531A1 (zh) 2018-10-19
AU2016311387A1 (en) 2018-03-29
EP3341017B1 (en) 2024-10-16
CN107921113A (zh) 2018-04-17
CA2996383A1 (en) 2017-03-02

Similar Documents

Publication Publication Date Title
US11701393B2 (en) Immunomodulatory compositions and methods of use thereof
US10946082B2 (en) Immunomodulatory compositions and methods of use thereof
RU2617058C2 (ru) Фармацевтическая композиция, содержащая комплекс полимерного носителя и переносимого вещества и по меньшей мере один белковый или пептидный антиген
JP2025061056A (ja) 異なる核酸アジュバントの組み合わせによる、新規Ｔｈ１誘導性アジュバントおよびその用途
CN101616687B (zh) 非特异性免疫刺激剂
US20100285055A1 (en) Activation of natural killer (NK) cells and methods of use
US20110293658A1 (en) Use of inkt or tlr agonists for protecting against or treating a disease such as acute infection or cancer
JP2011026328A (ja) オリゴヌクレオチド組成物および免疫応答の調節のためのそれらの使用
CN103990120B (zh) 抗感染剂及其用途
CA2996383C (en) Immunomodulatory compositions and methods of use thereof
EP4431111A1 (en) Probiotic as vaccine immunoadjuvant
HK1227730A1 (en) Immunomodulatory compositions and methods of use thereof
HK1227730B (en) Immunomodulatory compositions and methods of use thereof
KR20160069204A (ko) 인간 카텔리시딘 ll-37을 포함하는 면역 활성 유도제, 이를 포함한 경구 백신, 및 이를 이용한 면역 활성 유도 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190816

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190816

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20201006

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210803

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211029

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20211208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220705

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221104

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221107

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221129

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221227

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230124

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230130

R150 Certificate of patent or registration of utility model

Ref document number: 7223989

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250